达格列净在成人I型糖尿病患者中效果探讨  

Discussion on the Effect of Dapagliflozin in Adults with Type 1 Diabetes

作　　者：王健 WANG Jian(Department of Endocrinology,Dong'e County People's Hospital,Liaocheng,Shandong Province,252201 China)

机构地区：[1]东阿县人民医院内分泌科,山东聊城252201

出　　处：《系统医学》2020年第16期22-25,共4页Systems Medicine

摘　　要：目的观察达格列净在成人I型糖尿病患者治疗中的效果。方法该次临床研究工作选择2018年8月—2019年8月该院收治的92例成人I型糖尿病患者为例,将患者随机分为对照组和观察组,其中对照组的46例患者采用常规治疗方法,观察组患者则以对照组为基础,使用达格列净进行治疗。对比分析两组患者的临床治疗效果、空腹血糖值、糖化血红蛋白水平、餐后2 h血糖值、胰岛素用量等。结果观察组患者治疗的患者胰岛素使用量(0.6±0.13)U/(kg·d)显著低于对照组患者胰岛素使用量(0.8±0.17)U/(kg·d),差异有统计学意义(t=4.347,P=0.018);观察组患者的糖化血红蛋白水平(6.48±1.12)%、空腹血糖为(3.15±1.42)mmol/L、餐后2 h血糖(6.65±1.78)mmol/L、治疗后平均体重(72.19±3.95)kg均在正常范围内,且优于对照组(t=4.268、2.692、2.695、5.285,P<0.05);观察组患者腹泻1例、呕吐2例、恶心2例与对照组相同,观察组尿路感染1例、酮症发生1例低于对照组,且无严重酮症酸中毒反应。结论将达格列净应用在I型糖尿病患者的临床治疗中,能够显著提升治疗效果,改善患者的临床症状,有效控制空腹有血糖,并且能够预防低血糖事件的发生率,可以作为成人I型糖尿病胰岛素辅助治疗在临床应用,得到广大医护人员和患者的认可,值得临床积极推广和应用。Objective To observe the effect of dagliflozin in the treatment of adule with type I diabetes.Methods In this clinical research work,92 adult patients with type I diabetes admitted in our hospital from August 2018 to August 2019 were taken as an example.The patients were randomly divided into a control group and an observation group,of which 46 patients in the control group were used conventional treatment method,the patients in the observation group were treated with dapagliflozin based on the control group.The clinical treatment effect,fasting blood glucose level,glycated hemoglobin level,2h postprandial blood glucose level and insulin dosage of the two groups of patients were compared and analyzed.Results The amount of insulin used by the patients in the observation group(0.6±0.13)U/(kg·d)was significantly lower than that of the control group(0.8±0.17)U/(kg·d),the difference was statistically significant(t=4.347,P=0.018);the glycated hemoglobin level of the observation group was(6.48±1.12)%,the fasting blood glucose was(3.15±1.42)mmol/L,and the blood glucose 2 hours after the meal(6.65±1.78)mmol/L,after treatment The average body weight(72.19±3.95)kg was within the normal range and was better than the control group(t=4.268,2.692,2.695,5.285,P<0.05);the observation group had 1 case of diarrhea,2 cases of vomiting,and 2 cases of nausea.The control group was the same.One case of urinary tract infection and one case of ketosis in the observation group were lower than the control group,and there was no severe ketoacidosis reaction.Conclusion The application of dagliflozin in the clinical treatment of patients with type I diabetes can significantly enhance the therapeutic effect,improve the clinical symptoms of patients,effectively control fasting blood glucose,and can prevent the incidence of hypoglycemia events,can be used as an adjuvant treatment of insulin in adult type I diabetes in clinical applications,which is recognized by the majority of health care professionals and patients,and is worthy of activ

关 键 词：达格列净 I型糖尿病 效果观察 

分 类 号：R473.5[医药卫生—护理学]